The safety, pharmacokinetics, and efficacy of intraocular celecoxib

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 3, 2014, Pages 1409-1418

  Kim, Stephen J ^a   Toma, Hassanain ^a   Shah, Rohan ^a   Kompella, Uday B ^b   Vooturi, Sunil K ^b   Sheng, Jinsong ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Celecoxib; Inflammation; Intravitreal drug delivery; NSAIDS; Prostaglandins

Indexed keywords

CELECOXIB; NIMESULIDE; PROSTAGLANDIN E2; TRIAMCINOLONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS HUMOR; ARTICLE; CATARACT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ELECTRORETINOGRAM; ELECTROSPRAY MASS SPECTROMETRY; ENDOTOXIN-INDUCED UVEITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; INFLAMMATION; INTRAOCULAR PRESSURE; LEUKOCYTE COUNT; MALE; MICROSCOPY; NONHUMAN; PHOTORECEPTOR; PRIORITY JOURNAL; RABBIT; SENSORY SYSTEM ELECTROPHYSIOLOGY;

CELECOXIB; INFLAMMATION; INTRAVITREAL DRUG DELIVERY; NSAIDS; PROSTAGLANDINS;

ANIMALS; AQUEOUS HUMOR; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; ELECTRORETINOGRAPHY; INTRAVITREAL INJECTIONS; MALE; PYRAZOLES; RABBITS; RETINA; SULFONAMIDES; TREATMENT OUTCOME; UVEITIS;

EID: 84896332764     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-13667     Document Type: Article

References (31)

1. Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol. 2010;55:108-133.
2. Reddy R, Kim SJ. Critical appraisal of ophthalmic ketorolac in the treatment of pain and inflammation following cataract surgery. Clin Ophthalmol. 2011;5:751-758.
3. Kim SJ, Lo WR, Hubbard GB III, et al. Topical ketorolac in vitreoretinal surgery: a prospective, randomized, placebocontrolled, double-masked trial. Arch Ophthalmol. 2008;126: 1203-1208.
4. Schoenberger SD, Kim SJ. Nonsteroidal anti-inflammatory drugs for retinal disease. Int J Inflam. 2013;2013:281981.
5. Johnson EI, Dunlop ME, Larkins RG. Increased vasodilatory prostaglandin production in the diabetic rat retinal vasculature. Curr Eye Res. 1999;18:79-82.
6. Schoenberger SD, Kim SJ, Sheng J, Rezaei KA, Lalezary M, Cherney E. Increased prostaglandin E2 (PGE2) levels in proliferative diabetic retinopathy, and correlation with VEGF and inflammatory cytokines. Invest Ophthalmol Vis Sci. 2012; 53:5906-5911.
7. Kim SJ, Adams NA, Toma HS, et al. Safety of intravitreal ketorolac and diclofenac: an electroretinographic and histopathologic study. Retina. 2008;28:595-605.
8. Baranano DE, Kim SJ, Edelhauser HF, Durairaj C, Kompella UB, Handa JT. Efficacy and pharmacokinetics of intravitreal nonsteroidal anti-inflammatory drugs for intraocular inflammation. Br J Ophthalmol. 2009;93:1387-1390.
9. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A. 1999;96:272-277.
10. Ayalasomayajula SP, Kompella UB. Celecoxib, a selective cyclooxygenase- 2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin- induced diabetic rat model. Eur J Pharmacol. 2003; 458:283-289.
11. Chew EY, Kim J, Coleman HR, et al. Preliminary assessment of celecoxib and microdiode pulse laser treatment on diabetic macular edema. Retina. 2010;30:459-467.
12. Seedher N, Bhatia S. Solubility enhancement of Cox-2 inhibitors using various solvent systems. AAPS PharmSciTech. 2003;4:E33.
13. Smith CJ, Zhang Y, Koboldt CM, et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A. 1998;95:13313-13318.
14. Rouzer CA, Marnett LJ. Cyclooxygenases: structural and functional insights. J Lipid Res. 2009;50:S29-S34.
15. Chin MS, Nagineni CN, Hooper LC, Detrick B, Hooks JJ. Cyclooxygenase-2 gene expression and regulation in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2001;42:2338-2346.
16. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol. 2008;30:65-68.
17. Ambati J, Atkinson JP, Gelfand BD. Immunology of age-related macular degeneration. Nat Rev Immunol. 2013;13:438-451.
18. Yanni SE, Barnett JM, Clark ML, Penn JS. The role of PGE2 receptor EP4 in pathologic ocular angiogenesis. Invest Ophthalmol Vis Sci. 2009;50:5479-5486.
19. Monnier Y, Zaric J, Ruegg C. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: from the bench to the bedside and back. Curr Drug Targets Inflamm Allergy. 2005; 4:31-38.
20. Maloney SC, Fernandes BF, Castiglione E, et al. Expression of cyclooxygenase-2 in choroidal neovascular membranes from age-related macular degeneration patients. Retina. 2009;29: 176-180.
21. Kim SJ, Toma HS, Barnett JM, Penn JS. Ketorolac inhibits choroidal neovascularization by suppression of retinal VEGF. Exp Eye Res. 2010;91:537-543.
22. Rezaei KA, Toma HS, Cai J, Penn JS, Sternberg P, Kim SJ. Reduced choroidal neovascular membrane formation in cyclooxygenase-2 null mice. Invest Ophthalmol Vis Sci. 2011;52:701-707.
23. Cheng T, Cao W, Wen R, et al. Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat M̈uller cells. Invest Ophthalmol Vis Sci. 1998;39:581-591.
24. Kern TS, Miller CM, Du Y, et al. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes. 2007;56:373-379.
25. Amrite AC, Ayalasomayajula SP, Cheruvu NPS, Kompella UB. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest Ophthalmol Vis Sci. 2006;47:1149-1160.
26. Effects of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. The DAMAD Study Group. Diabetes. 1989;38: 491-498.
27. Hattori Y, Hashizume K, Nakajima K, Nishimura Y, Naka M, Miyanaga K. The effect of long-term treatment with sulindac on the progression of diabetic retinopathy. Curr Med Res Opin. 2007;23:1913-1917.
28. Schoenberger SD, Kim SJ, Sheng J, Calcutt MW. Reduction of vitreous prostaglandin E2 levels after topical administration of ketorolac 0.45%. JAMA Ophthalmol. In press.
29. Gupta P, Chawla G, Bansal AK. Physical stability and solubility advantage from amorphous celecoxib: the role of thermodynamic quantities and molecular mobility. Mol Pharm. 2004;1: 406-413.
30. Maier TJ, Tausch L, Hoernig M, et al. Celecoxib inhibits 5- lipoxygenase. Biochem Pharmacol. 2008;76:862-872.
31. The Age-Related Eye Disease Study Research Group. Risk factors associated with age-related nuclear and cortical cataract: a case-control study in the Age-Related Eye Disease Study. Age-Related Eye Disease Study Report Number 5. Ophthalmology. 2001;108:1400-1408.